Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Short-Term Debt & Capital Lease Obligation : $1.13 Mil (As of Dec. 2014)

View and export this data going back to 2007. Start your Free Trial

What is Omni Bio Pharmaceutical Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Omni Bio Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2014 was $1.13 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Omni Bio Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2014 was $1.66 Mil.

Omni Bio Pharmaceutical Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Omni Bio Pharmaceutical's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omni Bio Pharmaceutical Short-Term Debt & Capital Lease Obligation Chart

Omni Bio Pharmaceutical Annual Data

Trend

Dec06

Dec07

Dec08

Mar09

Mar10

Mar11

Mar12

Mar13

Mar14

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.02

Omni Bio Pharmaceutical Quarterly Data
	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	-	0.31	1.64	1.13

Omni Bio Pharmaceutical Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Omni Bio Pharmaceutical Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Omni Bio Pharmaceutical's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omni Bio Pharmaceutical Inc (GREY:OMBP) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

5350 South Roslyn, Suite 430, Greenwood Village, CO, USA, 80111

Website

http://www.omnibiopharma.com

Omni Bio Pharmaceutical Inc is a US-based biopharmaceutical company, which is engaged in the exploration of new methods of use of alpha-1 antitrypsin (AAT). It offers AAT, a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood to treat patients suffering from emphysema due to AAT-deficiency. Further, it focuses on the research and development efforts of advancing its first recombinant molecule, AAT and an Fc component of immunoglobulin (AAT-Fc 2) into clinical trials. Geographically these activities are functioned through the region of US.

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Headlines

No Headlines